Figure 1
Influence of an induction therapy with mycophenolate mofetil (MMF) or cyclophosphamide (CYC) on plasmablast and plasma cell counts. CD27++CD38++HLADRhigh plasmablast (A) and CD27++CD38++HLADRlow plasma cell counts (C) prior to and approximately 16 and 31 weeks after start of induction therapy with MMF. CD27++CD38++HLADRhigh plasmablast (B) and CD27++CD38++HLADRlow plasma cell counts (D) prior to and approximately 15 weeks after start of induction therapy with CYC. Statistical analyses were performed using the Wilcoxon’s matched pairs signed rank test and P-values <0.05 were considered significant.